Tag
A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful
This review synthesizes recent evidence on the neuroprotective effects of healthy dietary patterns (Mediterranean, MIND), the synergistic impact of lifestyle and pharmacotherapy (GLP-1), and systemic advances in acute stroke care and second
This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major ad
Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st
A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall
A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight re
The PECTUS-AI study demonstrates that AI-based identification of thin-cap fibroatheromas using OCT provides superior prognostic value for cardiovascular events compared to manual analysis, particularly when assessing the entire imaged coron
A randomized trial reveals that endoscopic radial artery harvesting for CABG leads to better patient-reported hand function and significantly fewer neurologic deficits compared to the traditional open technique, potentially redefining the s
The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective o
This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.
The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile
A 2025 systematic review and meta-analysis found that patients with primary aldosteronism whose renin rose after mineralocorticoid receptor antagonist therapy had substantially lower cardiovascular event rates and possibly lower mortality,
A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (<25 and <20 ml/min/1.73 m2) increased cardiovascular risk nearly twofold, but SGLT2 inhibitors reduced that risk and retained benefit regardl
In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu
In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.
In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults an
An updated meta-analysis evaluates the effects of 0.5 mg colchicine on clinical outcomes after acute myocardial infarction, showing reduced hospital readmission but increased diarrhea risk without significant impact on major cardiovascular
A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.
This meta-analysis reveals that β-blocker therapy reduces mortality and adverse cardiovascular events in myocardial infarction patients with mildly reduced left ventricular ejection fraction (40–49%), extending benefits beyond reduced LVEF
Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including
